Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.

Trial Details

NCT ID

NCT06908694

Phase

PHASE4

Sponsor

Hamilton Health Sciences Corporation

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Semaglutide Pen Injector

Locations (sample)

Hamilton, Ontario, Canada|43.25011,-79.84963

Key Eligibility Criteria

Have a physician diagnosis of PC
Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)
Elevated BMI
≥30kg/m2 or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →